Access
This article is part of Nature's premium content.
Published online 21 August 2009 | Nature | doi:10.1038/news.2009.852
News: Q&A
The low-down on the Sanofi-Aventis shake-up
Research chief Paul Chew talks about the drug company's future.
When pharmaceutical company Sanofi-Aventis unveiled plans on 30 June to reorganize its research and development (R&D) operations, the announcement was noticeably short on details. Officials at Sanofi, the world's fourth largest drug-maker by sales, promised partnerships with public and private institutions, but revealed little more.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
